Innogenetics buys HIV diagnostic range from AVANT:
This article was originally published in Clinica
Executive Summary
Belgian company Innogenetics' North American subsidiary, based in Atlanta, Georgia, has bought AVANT Immunotherapeutics' TRAx product line for an undisclosed amount in cash and royalties. Innogenetics will have worldwide rights to sell, market and manufacture the line. The range includes the TRAx CD4, which is used to measure the number of CD4 cells in the blood of HIV sufferers to monitor disease progression and to determine treatment. The TRAx system is an enzyme-linked immunoassay that uses monoclonal antibodies for the measurement of specific T-lymphocytes in blood.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.